A first-in-human clinical trial has shown encouraging results for a new T-cell therapy designed to treat aggressive pediatric brain cancers, including diffuse intrinsic pontine glioma (DIPG). The therapy uses a patient’s own immune cells to target three tumor proteins—WT1, PRAME, and survivin—helping overcome one of the biggest challenges in treating solid tumors. Researchers reported early signs of tumor control, with some patients remaining disease-free for years after treatment. The therapy was also well tolerated, causing fewer severe side effects than many existing brain tumor immunotherapies. While these are early findings, larger Phase 2 trials are needed to confirm its safety and effectiveness.
Read more at MedicalXpress